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Abstract
Background: The rate of neonatal overweight remains generally high in type 1 diabetes (T1DM). Since glycemic
control has improved over time other contributors need to be identified. Our aim is to evaluate the risk factors for
large-for-gestational age infants (LGA) in women with T1DM and to evaluate whether the rate of LGA decreased
over time.
Methods: Retrospective analysis of the medical files of pregnant women with T1DM attending our university
hospital form 01-01-1992 till 31-07-2014. The generalized mixed model was used to adjust for several pregnancies
over time in the same women. A multivariable model was used to evaluate independent risk factors for LGA.
Results: Over a 22-year period, 259 pregnancies in 180 T1DM women were identified. Mean diabetes duration of
women was 13.7 ± 7.1 years, with a mean age of 29.5 ± 5.2 years. Macrosomia (>4Kg) was present in 16.2 % of
deliveries, LGA was present in 45.2 % and these numbers did not change over time (resp. p = 0.19 and p = 0.70).
Over time, significant more women were overweight (23.3 % vs. 39.3 %, p = 0.009) and more women had excessive
weight gain during pregnancy (21.3 % vs. 37.7 %, p = 0.019). Compared to women with a non-LGA baby, women
with a LGA baby had a higher weight at delivery (84.1 ± 11.1 vs. 80.4 ± 10.8, p = 0.016), had more often excessive
weight gain (45.3 % vs. 25.2 %, p = 0.003) and had less strict glycaemic control in the first and third trimester
[HbA1c of resp. 49 ± 10 mmol/mol (6.7 % ±0.9) vs. 47 ± 8 mmol/mol (6.5 % ±0.8), p = 0.01 and 44 ± 5 mmol/mol
(6.2 % ±0.5) vs. 42 ± 6 mmol/mol (6.0 % ±0.6), p = 0.01]. In the forward multivariable analysis, excessive weight gain
[OR 1.95 (1.08–3.53), p = 0.027], HbA1c level in early [OR 1.43 (1.05–1.95), p = 0.023] and late pregnancy [OR 1.70
(1.07–2.71), p = 0.026] remained independent predictors for LGA.
Conclusions: LGA remains a frequent complication in T1DM. Excessive weight gain and HbA1c in early and late
pregnancy are important risk factors for LGA in our population. These findings highlight the importance of strict
maternal glycemic control and simultaneous striving to appropriate gestational weight gain to minimize the risk of
fetal overgrowth in T1DM pregnancies.
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Background
Due to improved medical care, outcomes in pregnant
women with type 1 diabetes (T1DM) have improved
substantially over the past decades [1–3]. Nevertheless,
the prevalence of macrosomia continues to increase [4].
Macrosomia can cause major problems during labor and
is associated with increased neonatal morbidity as well
as long-term increased risk of developing overweight
and type 2 diabetes (T2DM) [5]. Neonatal overweight in
T1DM is mainly caused by placental transfer of maternal
glucose but since glycemic control has improved over
time other contributors need to be identified [6]. In
healthy pregnant women obesity and excessive weight
gain in pregnancy predispose to macrosomia [7, 8]. Most
studies on this topic in women with diabetes include
T2DM patients or women with gestational diabetes
(GDM) and confirm the strong association between
obesity, excessive weight gain in pregnancy and fetal
overgrowth [9, 10]. On women with T1DM the evidence
is far more scarce. A large Swedish cohort study in
T1DM patients showed a positive relation between high
pre-pregnancy body mass index (BMI) and the risk of
fetal overgrowth [11]. Recently an observational study
identified excessive weight gain during pregnancy as an
independent risk factor for fetal overgrowth in T1DM
patients [12]. The aim of this study was therefore to
evaluate the risk factors for large-for-gestational age
infants (LGA) in our T1DM population and to evaluate
whether the rate of LGA decreased over time. Our
hypothesis was that the increasing prevalence of ma-
ternal overweight and excessive gestational weight gain,
independently of maternal glycemic control, might con-
tribute to the persistent high prevalence of LGA in
women with T1DM.
Methods
Analysis of the electronic medical files over a 22 year
period from 01-01-1992 till 31-07-2014 of all pregnant
women with T1DM attending the University Hospital
UZ Leuven. The study was approved by the Institutional
Review Board of UZ Leuven (ML 10676). Our study ad-
heres to the Helsinki Declaration of 1975. Due to the
retrospective nature of the study there was no need for
informed consent from the participants as in compliance
with the Belgian Law of December 8,1992 on the protec-
tion of privacy and the Belgian Law of August 22, 2002
on the rights of the patient.
Since 1999 a structured electronic medical file is used
in our center. From 1992 till 2012 data were prospect-
ively collected in the database. From 2012 onwards all
data were retrospectively collected. Due to lack of data
from women with late referrals, only pregnant T1DM
women with antepartum follow-up < 12 weeks at UZ
Leuven were included in the study. Other exclusion
criteria were women with GDM, T2DM, hereditary dia-
betes, secondary diabetes and use of a peritoneal insulin
infusion pump. Because we aimed to analyze the risk fac-
tors for LGA, we only included life births and single
births, also excluding women with abortion due to con-
genital malformations, mors in utero and multiple births.
UZ Leuven Hospital is a tertiary care facility with an
average of 2400 deliveries per year and is equipped with
a High Risk Obstetrics department. Women with T1DM
are intensively followed up during and after pregnancy
by a multidisciplinary team with an experienced dia-
betologist, obstetrician and neonatologist using stan-
dardized protocols. Women with T1DM are advised to
carefully plan their pregnancy. In our center, women
with active pregnancy wish are therefore seen monthly
at the multidisciplinary diabetes clinic with an experi-
enced diabetologist, diabetes nurse and dietician. The
general policy in our center is that contraception can
only be stopped when an HbA1c < 53 mmol/mol (7 %) is
achieved during at least two consecutive monthly con-
trols. If feasible, a pre-pregnancy HbA1c < 48 mmol/mol
(6.5 %) is aimed for. When planning pregnancy and dur-
ing pregnancy, women are asked to perform self-
monitoring of plasma glucose seven times daily (before
and 2 h after each meal and at bedtime.). The glycemic
targets used in pregnancy are fasting and premeal 3.3–
5.5 mmom/l, 2 h postprandial < 6.7 mmol/l and before
bedtime 6.0–8.0 mmol/l. From the second trimester on
an HbA1c ≤ 42 mmol/mol (6 %) is aimed for. Once preg-
nant, women are seen two weekly at the multidisciplin-
ary diabetes clinic. In our center an insulin pump is the
preferred treatment to optimize glycemic control in
pregnancy, unless excellent control on multiple daily in-
jections (MDI). Most women with T1DM are therefore
already treated with an insulin pump before pregnancy.
As short acting insulin the insulin analogues Aspart or
Lispro are used. For women on MDI, since 2011 insulin
Detemir is preferably used over insulin Glargine as the
long acting insulin analogue. Metformin is rarely used
during pregnancy in T1DM in our center and when used
this is discontinued at the end of the first trimester.
After the obstetrical booking visit at 6–8 gestational
weeks, pregnant T1DM women come for an antepartum
visit every 4 weeks until 20–22 gestational weeks, every
2 weeks until 32 gestational weeks and subsequently
weekly or twice weekly until delivery. Routine non-stress
tests are performed at all visits from 32 gestational
weeks onwards and all patients receive a minimum of
three ultrasound evaluations. After an uneventful preg-
nancy, induction of labor is offered to the large majority
of women at 38 gestational weeks. In case of complica-
tions, particularly hypertension, women are seen at least
twice-weekly at the day-ward or admitted to the ante-
partum ward; the timing of delivery is individualized in
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these cases. Indications for caesarean section, apart from
routine obstetrical indications (breech, etc.), include pre-
vious caesarean section and an unfavorable cervix, fetal
weight estimated to be LGA on the basis of the abdom-
inal circumference measurement, and severe maternal
disease. Over the 22 year follow up period the same
standardized protocols were used, except for changes in
policy concerning the peripartum glycemic control and
hospitalization at the neonatal intensive care. More
specifically, since 1999 a strict glycemic control was
aimed for during labor and delivery with preferably
continuation of the insulin pump. Since the year 2005,
provided that the Apgar scores were satisfactory and
gestational maturity was achieved, most neonates stay
with their mother. Before 2005 almost all neonates were
preventively hospitalized at the neonatology department
for a few days.
Outcomes were obtained from review of the electronic
database. Maternal characteristics recorded were age,
ethnicity, weight, BMI at first prenatal visit, overweight
(BMI ≥25 and < 29.9Kg/m2), obesity (BMI ≥30 Kg/m2),
weight gain (difference in weight between first prenatal
visit and the delivery) and parity. Excessive weight gain
was defined according to the most recent Institute of
Medicine (IOM) guidelines [13]. Other maternal data
that were recorded are: rates of preconception consult-
ation, intake of folium acid (started before or in the first
trimester), need for fertility treatment, smoking during
pregnancy, diabetes duration, year of delivery, insulin
dose (Unit/kg/24 h) in each pregnancy trimester, type of
insulin treatment (insulin pump or MDI), HbA1c before
pregnancy, HbA1c in each pregnancy trimester (prefera-
bly at week 8, week 21 and week 36). Other data
collected are the lipid profiles (mostly non-fasting) up to
1 year before pregnancy or in the first trimester (total
cholesterol, triglycerides, HDL cholesterol and LDL
cholesterol), the blood pressure at week 8, known dia-
betic retinopathy, known diabetic nephropathy (24 h
microalbuminuria >30 mg) and use of steroids.
The following maternal pregnancy outcomes were
recorded: pregnancy induced hypertension (PIH) (blood
pressure ≥ 140/90 mmHg), preeclampsia (hypertension +
proteinuria or in combination with reduced growth or
HELPP-syndrome), preterm delivery (<37 weeks of ges-
tation), caesarean sections (primary caesarean sections
and total number combining primary and secondary
caesarean sections). The following neonatal pregnancy
outcomes were recorded: birth weight, gestational age,
sex, macrosomia (birth weight > 4 kg), LGA (birth
weight >90 percentile according to validated Flemish
growth charts adjusted for sex and parity) [14], small for
gestational age (birth weight <10 percentile according to
validated Flemish growth charts adjusted for sex and
parity) [14], Apgar score (five minutes), admission at the
neonatal intensive care unit (NICU), hypoglycemia
(defined as need of intravenous glucose) and congeni-
tal malformations.
To analyze the evolution of pregnancy outcomes over
time, the 22 year period was divided in 4 different time
periods. Due to changes in policy over time in our
hospital, the following division was made: 1992–1998,
1999–2004 since the stricter peripartum glycemic man-
agement, 2005–2009 since most neonates stay with their
mother and the last 5 years from 2010–2014.
HbA1c was during the study time period measured by
different techniques. From 1992 till March 1996 a home-
made method was used based on the Jeppson method
(Pharmacia Mono S kolom, cation exchange). From
March 1996 till May 2002 the immunoassay method
Unimate HbA1c of Roche was used (Cobas Integra 400).
From May 2002 till August 2007, the immunoassay
method Dimension HA1Cof . Dade Behring was used.
From August 2007 till August 2014, the reversed-phase
cation-exchange chromatography was used (ADAMS
HA-8160, Menarini Diagnostics Benelux). Since 1996
Hba1c is reported in compliance with the National
Glycohemoglobin Standardization Program [15].
Lipids were during the whole study period measured by
the same biomedical technique with also few changes
in the calibration methods that were used. Total choles-
terol was measured on Cobas 8000, Roche Diagnostics
by enzymatic colorimetric CHOD-PAP method, triglyc-
erides by enzymatic colorimetic GPO-PAP method,
HDL cholesterol by dextran sulfate/Mg precipitation
followed by enzymatic colorimetic CHOD-PAP reaction,
calculated LDL-cholesterol by Friedewald formula (Total
cholesterol—HDL cholesterol—Triglycerides / 4).
Statistical analyses
Continuous variables are presented as mean and standard
deviation. Normality was assessed by graphical explor-
ation. Categorical variables are presented as frequencies
and percentages.
Logistic regression models were used to analyze the
association between several clinical variables and LGA
as binary outcome. A random intercept for patient was
modeled to account for the fact that several pregnancies
in the same women may occur in the data set. First,
univariable analyzes were performed and secondly, a
multivariable model was constructed using a forward
model selection strategy, considering variables that re-
sulted significant from the univariable analyzes.
To evaluate differences between 4 time periods with
respect to clinical variables, generalized linear mixed
models were used for binary variables, and linear mixed
models for continuous variables with time period as a
factor. To evaluate the relation between the BMI cat-
egories (overweight, obesity) and excessive weight gain
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generalized linear mixed models were used with BMI
category as a factor.
Complete case analyses were performed, p-values <0.05
were considered significant and all tests were two-sided.
Statistical analyses were performed using SPSS 22.0.
Results
After exclusion of women with late referral after 12 weeks
or with follow up in another center (29), 229 women
with pregestational diabetes were identified. We fur-
ther excluded pregnant women with monogenetic
forms of diabetes (5), T2DM (28), neonatal diabetes
(1), secondary diabetes due to cystic fibrosis (2), a
T1DM patient on a peritoneal insulin pump (1), early
pregnancy loss due to abortion because of congenital
malformations (n = 4), mors in utero (4) and multiple
births (4). This leaves a cohort of 259 pregnancies in
180 T1DM women over a 22-year period. There were
low rates of diabetic retinopathy (2.7 %), diabetic ne-
phropathy (3.9 %), congenital malformations (2.7 %)
and Apgar scores < 7 (1.5 % of baby’s).
Table 1 gives an overview of the general character-
istics of the whole cohort and the evolution over time
using 4 time categories. Missing data were scarce
(<5 %) except for the lipid measurements (n = 93) and
insulin dose in the third trimester (n = 40). The ma-
jority of women were Caucasian with exception of 8
North African women. 11.6 % of women received a
fertility treatment. Insulin pumps were used in 84.6 %
of pregnancies. 90 % of women had a preconception
consultation. Despite an active policy of pregnancy
planning, in 29 % of pregnancies the glycemic control
at time of conception was above the target HbA1c of
53 mmol/mol (7 %). Mean diabetes duration of women
was 13.7 ± 7.1 years with a mean age of 29.5 ± 5.2 years,
both increased over the years. Over time, significant more
women were overweight and more women had excessive
weight gain during pregnancy. Over time women had
a lower mean LDL cholesterol (125.3 ± 20.7 mg/dL vs.
89.2 ± 25.0 mg/dL, p = 0.001) and lower levels of
triglycerides (118.3 ± 60.3 mg/dl vs. 76.1 ± 35.4 mg/dl,
p = 0.03). BMI categories overweight and obesity were
both a risk factor for excessive weight gain compared
to normal weight women (BMI < 25) with an odds
ratio (OR) of 4.04 (CI 2.19–7.46, p < 0.001) for overweight
women and an OR of 5.07 (CI 2.04–12.61, p < 0.001) for
obese women.
Table 2 gives an overview of the pregnancy outcomes
of the whole cohort. The missing data are scarce (<5 %).
Macrosomia was present in 16.2 % of women, LGA was
present in 45.2 % and 67.2 % received a cesarean section.
These numbers did not change significantly over time.
Neonatal hypoglycaemia decreased since 1999 due to a
stricter glycaemic management peripartum. The NICU
admissions decreased since 2005 due to the change in
policy in our center.
Table 1 The characteristics of the whole cohort of type 1 diabetes and evolution over time
1992-2014 1992-1998 1999-2004 2005-2009 2010-2014 P value
(n = 259) (n = 74) (n = 64) (n = 59) (n = 62)
Duration of Diabetes 13.7 ± 7.1 11.7 ± 5.8 13.7 ± 7.5 13.3 ± 6.7 15.4 ± 8.9 0.002
Maternal age at delivery (years) 29.5 ± 5.2 28.7 ± 3.9 29.7 ± 3.7 29.6 ± 4.2 30.4 ± 4.9 0.03
Weight trimester 1 (kg) 69.9 ± 10.8 67.8 ± 10.0 70.0 ± 10.7 71.4 ± 10.6 70.7 ± 11.9 0.003
Weight at delivery (kg) 82.1 ± 11.1 78.4 ± 9.6 83.4 ± 11.9 85.3 ± 11.3 82.3 ± 10.7 0.001
BMI before pregnancy (kg/m2) 25.3 ± 3.8 24.9 ± 3.7 25.5 ± 3.8 25.3 ± 3.6 25.4 ± 4.2 0.12
Obesity 10.9 % (n = 28) 9.6 % (n = 7) 14.1 % (n = 9) 6.8 % (n = 4) 13.1 % (n = 8) 0.48
Overweight 33.9 % (n = 87) 23.3 % (n = 17) 28.1 % (n = 18) 47.5 % (n = 28) 39.3 % (n = 24) 0.009
Excessive weight gain 34.4 % (n = 91) 21.3 % (n = 15) 42.2 % (n = 27) 40.4 % (n = 25) 37.7 % (n = 24) 0.019
HbA1c before pregnancy mmol/mol (%) 52 ± 10 51 ± 10 53 ± 12 50 ± 6 53 ± 12 0.24
(6.9 ± 0.9) (6.8 ± 0.9) (7.0 ± 1.1) (6.7 ± 0.6) (7.0 ± 1.1)
HbA1c trimester 1 mmol/mol (%) 49 ± 8 46 ± 8 51 ± 11 48 ± 5 50 ± 10 0.05
(6.6 ± 0.8) (6.4 ± 0.8) (6.8 ± 1.0) (6.5 ± 0.5) (6.7 ± 0.9)
HbA1c trimester 2 41 ± 8 39 ± 7 41 ± 7 42 ± 7 42 ± 8 0.23
mmol/mol (%) (5.9 ± 0.7) (5.7 ± 0.7) (5.9 ± 0.6) (6.0 ± 0.6) (6.0 ± 0.7)
HbA1c trimester 3 43 ± 7 41 ± 8 43 ± 7 44 ± 5 44 ± 7 0.10
mmol/mol (%) (6.1 ± 0.6) (5.9 ± 0.7) (6.1 ± 0.6) (6.2 ± 0.4) (6.2 ± 0.6)
BMI Body Mass Index, P value in bold indicates a statistically significant difference between the four time periods
Results are given as mean (SD) or % (n); Generalized linear mixed models were used for binary variables, and linear mixed models for continuous variables with
time period as a factor
Bold indicates statistically significant associations, p <0.05
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The difference in characteristics between LGA and
non-LGA pregnancies are summarized in Table 3. In the
univariable analysis, compared to women with a non-
LGA baby, women with a LGA baby had a significantly
higher weight at delivery and had significantly more
often excessive weight gain. HbA1c in the first and third
trimester was also significantly higher in women with a
LGA baby. No significant differences in BMI before
pregnancy (25.2 ± 3.7 vs. 25.3 ± 3.8, p = 0.80), duration of
diabetes (13.7 ± 6.7 years vs. 13.7 ± 7.4 years, p = 0.99), age
at delivery (29.5 ± 4.1 years vs. 29.6 ± 4.3 years, p = 0.92),
smoking habits (11.1 % vs. 18.3 %, p = 0.28), preconception
consultation (90.6 % vs. 89.4 %, p = 0.65) and lipid levels
(LDL cholesterol 87 ± 28 mg/dl vs 91 ± 28 mg/dl, p = 0.70,
triglycerides 79 ± 36 mg/dl vs. 85 ± 41, p = 0.60) were seen
between LGA and non-LGA groups. Using a forward
model selection strategy, the following variables that re-
sulted significant from the univariable analyzes were
included in the multivariable model: weight at delivery,
weight gain during pregnancy, excessive weight gain and
HbA1c during the first, second and third trimester of
pregnancy. In the forward multivariable analysis, excessive
weight gain (p = 0.027, OR 1.95, CI 1.08–3.53), HbA1c
level in early (p = 0.023, OR 1.43, CI 1.05–1.95) and late
pregnancy (p = 0.026, OR 1.70, CI 1.07–2.71) remained
independent predictors for LGA.
Based on a receiver operating characteristics (ROC)
curve for HbA1c in the first trimester with an area
under the curve (AUC) of 0.589, a HbA1c ≥ 40 mmol/
mol (5.8 %) had the best sensitivity and specificity
combined of resp. 94,5 % and 12,7 % to predict a LGA
outcome but with a low positive predictive value of
47.7 %. Based on a ROC curve for HbA1c in the third
trimester with an AUC of 0.584, a HbA1c ≥ 36 mmol/
mol (5.4 %) had the best sensitivity and specificity
combined of resp. 97,1 % and 13,4 % to predict a
LGA outcome but with a low positive predictive value
of 47.6 %.
Discussion
We show that LGA remains a frequent complication in
T1DM. Our study shows that excessive weight gain and
HbA1c in early and late pregnancy are independent risk
factors for LGA in our population. Despite a generally
good glycemic control, the prevalence of overweight
women and excessive weight gain during pregnancy
increased over the years in our population. Studies in
women with pregestational diabetes or gestational dia-
betes confirm the strong association between obesity,
excessive weight gain in pregnancy and fetal overgrowth
[9, 10, 16]. Compared to women with T2DM, women
with T1DM have generally a higher diabetes duration, a
more variable glycaemic control and therefore often a
higher HbA1c during pregnancy [17]. More data are
therefore necessary to evaluate whether overweight and
excessive weight gain are also independent predictors for
LGA in women with T1DM. Recently a Danish observa-
tional study in 115 women with T1DM identified ex-
cessive weight gain during pregnancy as an independent
risk factor for fetal overgrowth in T1DM [12]. Our study
in a cohort of 259 pregnancies with T1DM shows a
high rate of excessive weight gain during pregnancy and
Table 2 The pregnancy outcomes in the whole cohort of women with type 1 diabetes and evolution over time
Outcome 1992-2014 1992-1998 1999-2004 2005-2009 2010-2014 P value
(n = 259) (n = 74) (n = 64) (n = 59) (n = 62)
WOMEN
Pregnancy induced hypertension 12.7 % (n = 33) 16.2 % (n = 12) 21.9 % (n = 14) 5.1 % (n = 3) 6.5 % (n = 4) 0.033
Pre-eclampsia 8.1 % (n = 21) 8.1 % (n = 6) 4.7 % (n = 3) 8.5 % (n = 5) 11.3 % (n = 7) 0.55
Preterm delivery 19.7 % (n = 51) 21.6 % (n = 16) 15.6 % (n = 10) 22.0 % (n = 13) 19.4 % (n = 12) 0.83
Caesarean section 67.2 % (n = 174) 68.9 % (n = 51) 73.4 % (n = 47) 59.3 % (n = 35) 66.1 % (n = 41) 0.70
Primary Caesarean section 46.3 % (n = 120) 52.7 % (n = 39) 48.4 % (n = 41) 30.5 % (n = 18) 51.6 % (n = 32) 0.038
FETAL
Male 53.7 % (n = 139) 47.3 % (n = 35) 59.4 % (n = 38) 50.8 % (n = 30) 58.1 % (n = 36) 0.48
Gestational age at birth (weeks) 37.0 ± 1.4 36.7 ± 1.5 37.1 ± 1.1 37.2 ± 1.5 37.2 ± 1.4 0.35
Birth weight (g) 3458 ± 605 3454 ± 652 3399 ± 649 3462 ± 596 3518 ± 511 0.57
LGA infant 45.2 % (n = 117) 50.0 % (n = 37) 35.9 % (n = 23) 40.7 % (n = 24) 53.2 % (n = 33) 0.19
Macrosomia 16.2 % (n = 42) 17.6 % (n = 13) 15.6 % (n = 10) 13.6 % (n = 8) 17.7 % (n = 11) 0.92
Admissions NICU 66.3 % (n = 171) 97.3 % (n = 72) 79.7 % (n = 51) 40.7 % (n = 24) 39.3 % (n = 24) 0.001
Neonatal hypoglycaemia 29.0 % (n = 67) 42.6 % (n = 20) 28.6 % (n = 18) 25.4 % (n = 15) 22.6 % (n = 14) 0.18
NICU neonatal intensive care unit, LGA large-for-gestational age infant
Results are given as mean (SD) or % (n); P value in bold indicates a statistically significant difference between the four time periods. Generalized linear mixed
models were used for binary variables, and linear mixed models for continuous variables with time period as a factor
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confirms the impact of excessive weight gain on fetal over-
growth, independent of maternal glycemic control in early
and late pregnancy in T1DM. In addition, our study shows
that overweight and obese women often have the highest
prevalence of excessive weight gain. This highlights the
need for individualized preconception counseling to limit
weight gain in these women [18].
In GDM maternal lipids in the third pregnancy trimes-
ter have also been shown to be strong determinants of
fetal growth [19]. Our study found no relationship be-
tween lipid profile and LGA, possibly due to the high
number of missing data on the lipid profile.
Glycemic control in early and late pregnancy are major
risk factors for LGA in our study population. The major-
ity of our T1DM population was treated with an insulin
pump and the glycemic control in our cohort was gener-
ally appropriate. However more data are necessary on
the most optimal glycemic targets in each trimester. A
large prospective study with >700 women with T1DM
showed significant increasing rates of LGA with an
HbA1c ≥ 42 mmol/mol (6,0 %) at 26 and 34 weeks gesta-
tion [20]. In our study, the highest sensitivity to predict
LGA was seen at an HbA1c < 42 mmol/mol (6 %) but
with a low positive predictive value. Such a strict gly-
cemic control is often challenging to reach since insulin
is associated with an increased risk for hypoglycemia
and weight gain [21]. New technologies might help to
improve pregnancy outcomes but there is currently
insufficient evidence that intermittent use of real-time
continuous glucose monitoring in T1DM pregnancies
can improve pregnancy outcomes [22].
Overweight and obesity are becoming an pandemic
problem. In our study the number of overweight T1DM
women almost doubled during the study period. This is
twice as high as seen in the background population in
Flanders [23]. In contrast, the rate of obesity remained
stable through the years, similar with the frequency seen
in healthy pregnant women in Flanders [23]. Both GDM
and maternal obesity are independently associated with
adverse pregnancy outcomes [24]. In a large database of
3457 T1DM pregnancies the incidence of LGA increased
with greater BMI category [11]. In our study BMI was
not an independent risk factor for LGA but this might
be due to the rather small number of obese women in
our cohort.
Strengths of the study are the detailed characterization
of a large cohort with T1DM over more than 20 years. A
multivariable model was used to evaluate independent
risk factors for LGA. A limit of the study is the retro-
spective nature of the analysis. However most data were
Table 3 The difference in maternal characteristics between LGA and non-LGA pregnancies
Predictor LGA Non LGA OR CI P value
(n = 117) (n = 142)
Weight first visit (kg) 70.9 ± 10.6 69.0 ± 10.9 1.01 0.99–1.04 0.25
Weight at delivery (kg) 84.1 ± 11.1 80.4 ± 10.8 1.03 1.01–1.06 0.016
BMI before pregnancy (kg/m2) 25.2 ± 3.7 25.3 ± 3.8 0.99 0.92–1.06 0.80
Obesitya 11.1 % (n = 13) 10.7 % (n = 15) 1.01 0.44–2.32 0.99
Overweighta 32.5 % (n = 38) 35.0 % (n = 49) 1.29 0.76–2.18 0.35
Weight gain during pregnancy (kg) 13.2 ± 4.8 11.4 ± 5.2 1.08 1.02–1.13 0.008
Excessive weight gain 45.3 % (n = 53) 25.2 % (n = 38) 2.22 1.29–3.70 0.003
HbA1c before pregnancy mmol/mol (%) 53 ± 10 51 ± 11 1.28 0.95–1.72 0.10
(7.0 ± 0.9) (6.8 ± 1.0)
HbA1c trimester 1 mmol/mol (%) 50 ± 10 48 ± 8 1.49 1.10–2.02 0.010
(6.7 ± 0.9) (6.5 ± 0.8)
HbA1c trimester 2 mmol/mol (%) 42 ± 7 40 ± 8 1.61 0.98–2.65 0.06
(6.0 ± 0.6) (5.8 ± 0.7)
HbA1c trimester 3 mmol/mol (%) 44 ± 6 42 ± 7 1.82 1.16–2.86 0.010
(6.2 ± 0.5) (6.0 ± 0.6)
HbA1c < 42 mmol/mol (6 %) trimester 1 12.7 % (n = 14) 25.4 % (n = 35) 0.47 0.26–0.86 0.015
HbA1c < 42 mmol/mol (6 %) trimester 2 50.9 % (n = 56) 67.4 % (n = 93) 0.47 0.27–0.80 0.005
HbA1c < 42 mmol/mol (6 %) trimester 3 30.1 % (n = 31) 40.9 % (n = 52) 0.61 0.37–1.02 0.06
LGA large-for-gestational-age infant, BMI Body Mass Index
Results are given as mean (SD) or % (n); Bold indicates statistically significant associations, p < 0.05
Odds ratio (95 %)
areference category: normal weight with BMI < 25 kg/m2
Logistic regression models were used to analyze the association between several clinical variables and LGA as binary outcome
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collected prospectively. In our cohort we included women
with diabetic nephropathy and pre-eclampsia, which might
have underestimated the LGA rate since these conditions
have a restrictive impact on birth weight. However num-
bers were small and this is therefore unlikely to have an
impact on the risk factors for LGA. Whether the results are
applicable to other populations with T1DM needs to be
further explored. Our population consists of relative healthy
T1DM patients with generally a good glycemic control and
low prevalence of obesity.
Conclusions
LGA remains a frequent complication in T1DM. Excessive
weight gain and HbA1c in early and late pregnancy are
important risk factors for LGA in our population. Our
findings highlight the importance of strict maternal gly-
cemic control during pregnancy and simultaneous striving
to appropriate gestational weight gain to minimize the risk
of fetal overgrowth in T1DM pregnancies.
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